Abstract Library

#2887 CHOI Criteria Are More Accurate Than RECIST in Advanced Pancreatic Neuroendocrine Tumors Treated with Sunitinib: Data from the CRIPNET-GETNE1504 Study

Introduction: Comparative data suggest greater accuracy of Choi vs RECIST in some cancers such as pancreatic neuroendocrine tumors (panNET) treated with antiangiogenic agents.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Jimenez-Fonseca P, Fernandez del Valle A, Solis M, Garcia Carbonero R, Custodio A,

Keywords: CHOI, RECIST, Response, Sunitinib, Survival,

#2840 A Real-World Study of Patients with Carcinoid Syndrome at King’s College Hospital on Long-Term Telotristat Therapy

Introduction: Telotristat ethyl is a tryptophan hydroxylase inhibitor that has been shown to be effective against symptoms of carcinoid syndrome refractory to standard somatostatin analogue therapy by directly inhibiting serotonin production. While clinical trials have established short-term efficacy of the drug, we report an exploratory real-world study of 15 patients with metastatic neuroendocrine tumours on long-term Telotristat (median duration=8 months).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Hota S, Cananea E, Martin W, Clement D, Solis B,

Keywords: Neuroendocrine tumours, carcinoid syndrome, telotristat ethyl,

#2235 Efficacy of Sunitinib Correlated with Clinical, Radiological Variables, Dose-Intensity and Treatment Time in Advanced Grade 1-2 Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study NCT02841865)

Introduction: Sunitinib has been shown to be effective in advanced pancreatic neuroendocrine tumors (PNETs) but it is not well known how dose-intensity and treatment time influence the results.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Jimenez-Fonseca P, Solis Hernandez M, Fernandez del Valle A, Garcia-Carbonero R, Matos I,

Keywords: PNET, sunitinib, dose-intensive, progression-free survival,

#2217 Prognostic Impact of CHOI Response Criteria Compared to RECIST in Grade 1-2 Advanced Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study-NCT02841865)

Introduction: Response Evaluation Criteria In Solid Tumors (RECIST) are not presumably the most optimal option for predicting the benefit of antiangiogenic drugs in neuroendocrine tumors (NETs), given that tumor shrinkage is not frequent, and qualitative changes in tumor tissues are to be expected.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Carmona-Bayonas A, Fernandez del Valle A, Solis M, Matos I, Garcia-Carbonero R,

Keywords: CHOI criteria, pancreatic neuroendocrine tumor, RECIST, response, survival,

#2193 Advanced Gastric Neuroendocrine Carcinoma: A Diagnostic and Management Conundrum

Introduction: Gastric neuroendocrine carcinomas are rare tumors with a high malignant trait and poor prognosis. Endogenous hypercortisolism associated with neuroendocrine carcinomas can have a negative impact on patients' survival.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Lambrescu I, Martin S, Nitipir C, Terzea D, Cima L,

Keywords: gastric neuroendocrine carcinoma, hypercortisolism, Cushing disease, ectopic ACTH,